THE RELATIONSHIP OF SERUM URIC ACID TO SUBCLINICAL BLOOD LEAD

Rheumatology ◽  
1981 ◽  
Vol 20 (4) ◽  
pp. 208-210 ◽  
Author(s):  
MICHAEL D. BAKER ◽  
JOHN R. JOHNSTON ◽  
ALLAN E. MACLATCHY ◽  
BASIL N. BEZUIDENHOUT
2004 ◽  
Vol 34 (9) ◽  
pp. 874 ◽  
Author(s):  
Tae Woo Yoo ◽  
Ki Chul Sung ◽  
Young Choon Kim ◽  
Sang Tai Hwang ◽  
Se Yong Oh ◽  
...  

2021 ◽  
Author(s):  
Shengqiang Gao ◽  
Kuvaneshan Ramen ◽  
Shian Yu ◽  
Jiansheng Luo

Abstract Background: Non-alcoholic fatty liver disease (NAFLD) is linked to some metabolic disorders. Herein, we explored the relationship of levels of serum uric acid (SUA)with NAFLD in a population of non-obese Chinese. Methods: This was a cross-sectional study that involved 183,903 Chinese men and women with an average age of 40.98 years who underwent physical examinations at a health screening center at Wenzhou People’s Hospital. We defined NAFLD by ultrasound detection of steatosis. We employed univariate analysis along with multivariate Cox proportional hazards analyses to investigate the relationship of SUA level with NAFLD. Moreover, we employed the receiver operating characteristic curve to establish the SUA cutoffs of estimating NAFLD. Results: Overall, 25,501 participants (13.9%) had NAFLD. The NAFLD ORs were 1.47 (95% CI 1.35 to 1.59), 2.01 (95% CI 1.85 to 2.18) and 2.77 (95% CI 2.55 to 3.02) compared with Q1.AUC values for SUA ratios was 0.728. The optimal SUA level cut-off value for identification of NAFLD was 287.5, with a specificity and a sensitivity of 60.7% and 73.9%, respectively.Conclusion: High Serum uric acid levels shows positive correlation with NAFLD. SUA constitutes a cheap, simple, non-invasive, as well as a beneficial biomarker that could be utilized to forecast NAFLD in the non-obese Chinese population.


1985 ◽  
Vol 38 (4) ◽  
pp. 281-288 ◽  
Author(s):  
Siegfried Heyden ◽  
Nemat O. Borhani ◽  
H.A. Tyroler ◽  
Kenneth A. Schneider ◽  
Herbert G. Langford ◽  
...  

2014 ◽  
Vol 47 (6) ◽  
pp. 383-388 ◽  
Author(s):  
Erdim Sertoglu ◽  
Cemal Nuri Ercin ◽  
Gurkan Celebi ◽  
Hasan Gurel ◽  
Huseyin Kayadibi ◽  
...  

1982 ◽  
Vol 35 (3) ◽  
pp. 173-178 ◽  
Author(s):  
Mitsuo Okada ◽  
Kazuo Ueda ◽  
Teruo Omae ◽  
Moriyuki Takeshita ◽  
Yasuo Hirota

1968 ◽  
Vol 45 (4) ◽  
pp. 520-528 ◽  
Author(s):  
Allen R. Myers ◽  
Frederick H. Epstein ◽  
H.J. Dodge ◽  
William M. Mikkelsen

2013 ◽  
Vol 16 (01) ◽  
pp. 1350004 ◽  
Author(s):  
Matthew B. Carroll ◽  
Mauricio DeCastro-Pretelt ◽  
Nicole Hust ◽  
Freddie Smith ◽  
Tigist Belema ◽  
...  

Background: There is evidence linking xanthine oxidase (XO) single nucleotide polymorphisms (SNPs) to multiple medical conditions. The relationship of XO SNPs to hyperuricemia/gout is limited. An in vitro study of serum from healthy adults found two XO SNPs at 2107A > G and 3662A > G associated with a two-fold higher activity of the enzyme. Materials and Methods: The main outcomes of this study were to determine if the presence of either 2107A > G or 3662A > G XO SNP led to the occurrence of hyperuricemia, gout, or necessitated a higher dose of XO inhibitor (XOI) to achieve a treatment goal of less than 6 mg/dL. A total of 72 patients were enrolled in the hyperuricemia/gout group; 41 in the control group. XO SNPs were amplified and sequenced. Patient interviews and chart reviews gathered demographic data, use of XOI, comorbidities, and serum uric acid levels. Results: The 2107A > G SNP was detected in six patients with hyperuricemia/gout and two patients in the control group. There was no association between either XO SNP with the occurrence of hyperuricemia/gout (p = 0.709). A higher dose of allopurinol was needed to achieve a treatment serum uric acid goal of less than 6 mg/dL (p = 0.049). The 3662A > G SNP was not identified in any patients in the either group of the study. Conclusion: While the presence of 2107A > G SNP had no relationship to hyperuricemia or gout in our cohort it did affect the dose of allopurinol needed to achieve a treatment goal of less than 6 mg/dL. The 3662A > G SNP was not identified in our sample.


Author(s):  
Menglin Jiang ◽  
Dandan Gong ◽  
Yu Fan

AbstractElevated serum uric acid (SUA) levels may increase the risk of prehypertension. However, the findings from these studies remain conflicting. The objective of this study was to determine the relationship between SUA levels and risk of prehypertension by conducting a meta-analysis. We conducted a comprehensive literature search of PubMed, Embase, China National Knowledge Infrastructure, VIP, and the Wangfang database without language restrictions through May 2015. Observational studies assessing the relationship between SUA levels and prevalence of prehypertension were included. Pooled adjust odds ratio (OR) and corresponding 95% confidence intervals (CI) of prehypertension were calculated for the highest vs. lowest SUA levels. Prehypertension was defined as systolic blood pressure (BP) ranging from 120 to 139 mmHg or diastolic BP ranging from 80 to 89 mmHg. Eight cross-sectional studies with a total of 21,832 prehypertensive individuals were included. Meta-analysis showed that elevated SUA levels were associated with increased risk of prehypertension (OR: 1.84; 95% CI: 1.42–2.38) comparing the highest vs. lowest level of SUA levels. Subgroup analyses showed that elevated SUA levels significantly increased the risk of prehypertension among men (OR: 1.60; 95% CI: 1.12–2.21) and women (OR: 1.59; 95% CI: 1.17–2.16). Elevated SUA levels are positively associated with the risk of prehypertension in the general population. However, more well-designed longitudinal studies are needed before a definitive conclusion can be drawn due to the cross-sectional studies included are susceptible to bias.


Sign in / Sign up

Export Citation Format

Share Document